

# Synagis Criteria

## Synagis Form

---

1. Synagis can be administered in any setting where IM injections are appropriate.

A ) How old is the patient and is the patient at risk for RSV infection?

At least one of the following criteria must be met before the patient is considered "at risk" for RSV:

1. Patient is <24 months of age at start of therapy and has chronic lung disease, especially if on oxygen chronically or if only off oxygen <3-6 months.
2. Patient is < 1 year of age at start of therapy with a gestational age of < 28 weeks or < 1 year and has a history of concomitant medical problems (e.g. Heart surgery or caffeine administration for respiratory stimulation within the last year).
3. Patient is < 6 months of age at start of therapy with a gestational age of 28-32 weeks or has a gestational age of 33-36 weeks and subject to additional health risk\*.
4. Patient is < 3 months of age at the start of therapy with gestational age of 32-36 weeks and concomitant medical problems.
5. Patient can not be approved if they are currently receiving immunoglobulin infusions. Immunity should be acquired through those infusions.

\* Additional Health Risk Include: school age siblings; crowding in the home; daycare attendance; exposure to tobacco in the home and/or multiple births.

B) How long is the treatment necessary?

Treatment can only be approved for the RSV season. Patient should receive monthly administrations throughout the RSV season, therefore approval period will be October 1st through May 31st of each year.

---

---

Rational Drug Therapy Program  
West Virginia University School of Pharmacy  
P.O. Box 9511  
Morgantown, WV 26506-9511  
Phone 800 847 3859  
Fax 800 531 7787